These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3257526)

  • 41. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
    Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
    J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Konrad M; Bradley EC; Comis RL
    J Clin Oncol; 1990 Mar; 8(3):460-7. PubMed ID: 2407809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
    J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
    Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
    Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
    Parkinson DR; Abrams JS; Wiernik PH; Rayner AA; Margolin KA; Van Echo DA; Sznol M; Dutcher JP; Aronson FR; Doroshow JH
    J Clin Oncol; 1990 Oct; 8(10):1650-6. PubMed ID: 2213101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.
    Abrams JS; Rayner AA; Wiernik PH; Parkinson DR; Eisenberger M; Aronson FR; Gucalp R; Atkins MB; Hawkins MJ
    J Natl Cancer Inst; 1990 Jul; 82(14):1202-6. PubMed ID: 2194036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
    Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
    J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.
    Escudier B; Farace F; Angevin E; Charpentier F; Nitenberg G; Triebel F; Hercend T
    Eur J Cancer; 1994; 30A(8):1078-83. PubMed ID: 7654433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
    Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
    J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
    Aso Y; Tazaki H; Umeda T; Marumo K
    Prog Clin Biol Res; 1989; 303():681-8. PubMed ID: 2675018
    [No Abstract]   [Full Text] [Related]  

  • 55. Interleukin-2 therapy for advanced renal cell carcinoma: radiographic evaluation of response and complications.
    Davis SD; Berkmen YM; Wang JC
    Radiology; 1990 Oct; 177(1):127-31. PubMed ID: 2399311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
    Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
    J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
    Ilson DH; Motzer RJ; Kradin RL; Vogelzang NJ; Bajorin DF; Scher HI; Nanus D; O'Moore P; Marathias K; Bosl GJ
    J Clin Oncol; 1992 Jul; 10(7):1124-30. PubMed ID: 1607918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study.
    Punt KC; Jansen RL; De Mulder PH; Batchelor D; Galazka A; Bolhuis RL; Stoter G
    J Immunother (1991); 1992 Nov; 12(4):277-84. PubMed ID: 1477079
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
    Nakano E
    Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.